Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AGI-5198 + Trichostatin A |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AGI-5198 | AG5198|AGI 5198|IDH-C35 | IDH1 Inhibitor 8 | AGI-5198 is a selective inhibitor of mutant forms of IDH1, which decreases production of R-2HG, potentially leading to reduced growth of IDH1-mutant tumor cells (PMID: 23558169, PMID: 26368816, PMID: 31151327). | |
Trichostatin A | TSA | HDAC Inhibitor 45 | Trichostatin A (TSA) inhibits histone deacetylase (HDAC) activity, which may lead to decreased tumor cell proliferation and viability and reduced tumor growth (PMID: 11309348, PMID: 22158273, PMID: 32753022). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH1 R132H | glioblastoma | predicted - sensitive | AGI-5198 + Trichostatin A | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of AGI-5198 treatment in glioblastoma cells expressing IDH1 R132H led to decreased resistance to Trichostatin (TSA) treatment in culture, resulting in reduced cell viability (PMID: 31151327). | 31151327 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|